Cargando…

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC

PURPOSE: Neoadjuvant therapy (NAT) is considered the standard of care for patients with HER2-positive breast cancer (BC). However, there is no proven survival benefit of NAT compared to adjuvant therapy for the survival of patients with early-stage HER2-positive BC. This study aimed to compare the p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Shuyue, Li, Lun, Chen, Ming, Yang, Benlong, Chen, Jiajian, Liu, Guangyu, Shao, Zhimin, Wu, Jiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038764/ https://www.ncbi.nlm.nih.gov/pubmed/35429731 http://dx.doi.org/10.1016/j.breast.2022.03.015

Ejemplares similares

Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study
por: Sang, Yuting, et al.
Publicado: (2022)

Latissimus dorsi flap – the main force in breast reconstruction for breast tumor in Chinese population
por: Zheng, Shuyue, et al.
Publicado: (2023)

Treatment and survival outcomes in older women with primary breast cancer: A retrospective propensity score-matched analysis
por: Sang, Yuting, et al.
Publicado: (2022)

Immediate Breast Reconstruction After Neoadjuvant Chemotherapy: Factors Associated With Surgical Selection and Complications
por: Chi, Weiru, et al.
Publicado: (2023)

Clinicopathological and Survival Outcomes of Well-Differentiated Thyroid Carcinoma Undergoing Dedifferentiation: A Retrospective Study from FUSCC
por: Ma, Ben, et al.
Publicado: (2018)

Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy
por: Li, JunJie, et al.
Publicado: (2016)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
por: Xie, Yifan, et al.
Publicado: (2021)

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
por: Li, Junjie, et al.
Publicado: (2018)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
por: Li, Si, et al.
Publicado: (2018)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
por: Zhang, Wei, et al.
Publicado: (2017)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer()
por: Harbeck, Nadia
Publicado: (2022)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study
por: Pu, Ning, et al.
Publicado: (2023)

Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
por: Huang, Liang, et al.
Publicado: (2013)

Overall Survival Benefit in Rectal Cancer After Neoadjuvant Radiotherapy and Adjuvant Chemotherapy: A Propensity-Matched Population-Based Study
por: Chen, Zhiju, et al.
Publicado: (2020)

Is adjuvant chemotherapy better than neoadjuvant chemotherapy for those with node positive disease?
por: Zabell, Joseph, et al.
Publicado: (2018)

HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens
por: Laas, Enora, et al.
Publicado: (2021)

Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors
por: Sobash, Philip T., et al.
Publicado: (2022)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

No survival benefit could be obtained from adjuvant radiotherapy in esophageal cancer treated with neoadjuvant chemotherapy followed by surgery: A SEER-based analysis
por: Zheng, Si-Yue, et al.
Publicado: (2022)

Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
por: Chen, Yan, et al.
Publicado: (2018)

The Role of Mammographic Calcification in the Neoadjuvant Therapy of Breast Cancer Imaging Evaluation
por: Li, Jun-jie, et al.
Publicado: (2014)

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis
por: Debiasi, Márcio, et al.
Publicado: (2018)

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
por: Loo, Claudette E., et al.
Publicado: (2016)

Preoperative Splenic Density for the Prediction of Survival and Adjuvant Chemotherapy Benefits in Gastric Cancer
por: Zhang, Wei-teng, et al.
Publicado: (2020)

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer
por: Huang, Liang, et al.
Publicado: (2015)

In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program
por: Hao, Zhonglin, et al.
Publicado: (2023)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
por: Tateishi, Kaho, et al.
Publicado: (2023)

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
por: Kümmel, S, et al.
Publicado: (2006)

Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Lin, Jian-Xian, et al.
Publicado: (2022)

Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?
por: Melchior, Nicole M., et al.
Publicado: (2020)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Yan, Hui, et al.
Publicado: (2020)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

The Type of Breast Reconstruction May Not Influence Patient Satisfaction in the Chinese Population: A Single Institutional Experience
por: Yang, Benlong, et al.
Publicado: (2015)

RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients
por: Wang, Haibo, et al.
Publicado: (2022)

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
por: Wu, Jiong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9a982m0rooevngrvan3qa47et8